Physician profile
Marc Silverstein
NPI 1104869155
$3,053.08
in general payments reported to CMS, 2019-2025
15 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $100 · 2021: $491 · 2022: $797 · 2023: $575 · 2024: $235 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,013.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $697.83 | 2019-2023 | Skyrizi |
| Lilly USA, LLC | $341.28 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $249.21 | 2019-2024 | Dupixent |
| Janssen Scientific Affairs, LLC | $247.72 | 2019-2021 | |
| Ucb, INC. | $193.46 | 2022-2025 | |
| Pfizer INC. | $179.83 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $177.56 | 2021-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $152.90 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $146.94 | 2023 | |
| Dermavant Sciences, INC. | $122.31 | 2023 | Vtama |
| Incyte Corporation | $122.31 | 2023 | Opzelura |
| Galderma Laboratories, L.P. | $109.44 | 2024 | |
| Sun Pharmaceutical Industries INC. | $109.39 | 2022 | |
| Leo Pharma INC. | $107.78 | 2022 | |
| Genzyme Corporation | $95.12 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Silverstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.